New molecular therapies for hepatocellular carcinoma.

S. Torrecilla,J. Llovet,J. Llovet

DOI: https://doi.org/10.1016/j.clinre.2015.06.016

IF: 3.189

2015-09-01

Clinics and Research in Hepatology and Gastroenterology

Abstract:

What problem does this paper attempt to address?

Current approaches to assess HIV-1 persistence

Riddhima Banga,Francesco A Procopio,Matthieu Perreau

DOI: https://doi.org/10.1097/COH.0000000000000282

Abstract:Purpose of review: The persistence of HIV within long-lived HIV-infected CD4 T cells is the primary obstacle towards HIV eradication and numerous strategies are currently being evaluated to target and kill HIV-infected cells to ultimately find a cure. HIV reservoirs are classically quantified by standard methods such as integrated HIV DNA (Alu PCR) and/or quantitative viral outgrowth assay; however, recent technical advances may offer new opportunities to comprehensively assess the impact of clinical interventions. Recent findings: Digital droplet PCR, tat/rev-induced limiting dilution analysis, enhanced quantitative viral outgrowth assay, and whole genome sequencing technologies offer increased precision and/or higher sensitivity to quantify and characterize HIV reservoirs in antiretroviral therapy-treated HIV-infected patients. Summary: The objective of this review is to highlight the characteristics and limits of recent technical advances that may help to monitor the impact of clinical interventions in antiretroviral therapy-treated patients.
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

Christine Katlama,Steven G Deeks,Brigitte Autran,Javier Martinez-Picado,Jan van Lunzen,Christine Rouzioux,Michael Miller,Stefano Vella,Joern E Schmitz,Jeffrey Ahlers,Douglas D Richman,Rafick P Sekaly

DOI: https://doi.org/10.1016/S0140-6736(13)60104-X

2013-06-15

Abstract:Antiretroviral therapy for HIV infection needs lifelong access and strict adherence to regimens that are both expensive and associated with toxic effects. A curative intervention will be needed to fully stop the epidemic. The failure to eradicate HIV infection during long-term antiretroviral therapy shows the intrinsic stability of the viral genome in latently infected CD4T cells and other cells, and possibly a sustained low-level viral replication. Heterogeneity in latently infected cell populations and homoeostatic proliferation of infected cells might affect the dynamics of virus production and persistence. Despite potent antiretroviral therapy, chronic immune activation, inflammation, and immune dysfunction persist, and are likely to have important effects on the size and distribution of the viral reservoir. The inability of the immune system to recognise cells harbouring latent virus and to eliminate cells actively producing virus is the biggest challenge to finding a cure. We look at new approaches to unravelling the complex virus-host interactions that lead to persistent infection and latency, and discuss the rationale for combination of novel treatment strategies with available antiretroviral treatment options to cure HIV.
Advanced Therapies for Human Immunodeficiency Virus

Daniel Josef Lindegger

DOI: https://doi.org/10.3390/medsci12030033

2024-07-18

Abstract:Human Immunodeficiency Virus (HIV) remains a significant global health challenge with approximately 38 million people currently having the virus worldwide. Despite advances in treatment development, the virus persists in the human population and still leads to new infections. The virus has a powerful ability to mutate and hide from the human immune system in reservoirs of the body. Current standard treatment with antiretroviral therapy effectively controls viral replication but requires lifelong adherence and does not eradicate the virus. This review explores the potential of Advanced Therapy Medicinal Products as novel therapeutic approaches to HIV, including cell therapy, immunisation strategies and gene therapy. Cell therapy, particularly chimeric antigen receptor T cell therapy, shows promise in preclinical studies for targeting and eliminating HIV-infected cells. Immunisation therapies, such as broadly neutralising antibodies are being investigated to control viral replication and reduce reservoirs. Despite setbacks in recent trials, vaccines remain a promising avenue for HIV therapy development. Gene therapy using technologies like CRISPR/Cas9 aims to modify cells to resist HIV infection or eliminate infected cells. Challenges such as off-target effects, delivery efficiency and ethical considerations persist in gene therapy for HIV. Future directions require further research to assess the safety and efficacy of emerging therapies in clinical trials. Combined approaches may be necessary to achieve complete elimination of the HIV reservoir. Overall, advanced therapies offer new hope for advancing HIV treatment and moving closer to a cure.
Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection

Ruojing Bai,Shiyun Lv,Hao Wu,Lili Dai

DOI: https://doi.org/10.1155/2022/6952286

2022-05-31

Abstract:Since the first discovery of human immunodeficiency virus 1 (HIV-1) in 1983, the targeted treatment, antiretroviral therapy (ART), has effectively limited the detected plasma viremia below a very low level and the technique has been improved rapidly. However, due to the persistence of the latent reservoir of replication-competent HIV-1 in patients treated with ART, a sudden withdrawal of the drug inevitably results in HIV viral rebound and HIV progression. Therefore, more understanding of the HIV-1 latent reservoir (LR) is the priority before developing a cure that thoroughly eliminates the reservoir. HIV-1 spreads through both the release of cell-free particles and by cell-to-cell transmission. Mounting evidence indicates that cell-to-cell transmission is more efficient than cell-free transmission of particles and likely influences the pathogenesis of HIV-1 infection. This mode of viral transmission also influences the generation and maintenance of the latent reservoir, which represents the main obstacle for curing the infection. In this review, the definition, establishment, and maintenance of the HIV-1 LR, along with the state-of-the-art quantitative approaches that directly quantify HIV-1 intact proviruses, are elucidated. Strategies to cure HIV infection are highlighted. This review will renew hope for a better and more thorough cure of HIV infection for mankind and encourage more clinical trials to achieve ART-free HIV remission.
Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure

Marie Armani-Tourret,Benjamin Bone,Toong Seng Tan,Weiwei Sun,Maxime Bellefroid,Tine Struyve,Michael Louella,Xu G. Yu,Mathias Lichterfeld

DOI: https://doi.org/10.1038/s41579-024-01010-8

IF: 88.1

2024-02-11

Nature Reviews Microbiology

Abstract:Successful approaches for eradication or cure of HIV-1 infection are likely to include immunological mechanisms, but remarkably little is known about how human immune responses can recognize and interact with the few HIV-1-infected cells that harbour genome-intact viral DNA, persist long term despite antiretroviral therapy and represent the main barrier to a cure. For a long time regarded as being completely shielded from host immune responses due to viral latency, these cells do, on closer examination with single-cell analytic techniques, display discrete footprints of immune selection, implying that human immune responses may be able to effectively engage and target at least some of these cells. The failure to eliminate rebound-competent virally infected cells in the majority of persons likely reflects the evolution of a highly selected pool of reservoir cells that are effectively camouflaged from immune recognition or rely on sophisticated approaches for resisting immune-mediated killing. Understanding the fine-tuned interplay between host immune responses and viral reservoir cells will help to design improved interventions that exploit the immunological vulnerabilities of HIV-1 reservoir cells.

microbiology
Treatment of Human Immunodeficiency Virus-1: Current Challenges and Future Perspectives

Inês Pereira,Cristina Luxo

DOI: https://doi.org/10.4172/2155-6113.1000603

2016-01-01

Abstract:Today, HIV‑1 infection maintains its status as a grave public health problem. The development of effective antiretroviral drugs has greatly increased life expectancy of infected patients by arresting disease progression, but treatment is not able to eliminate the virus from the body, requiring lifelong adherence to prevent viral rebound and its consequent damage on the host immune system. The ability of the virus to remain latent in cellular reservoirs is a major obstacle in the development of curative therapies, in part because there is still a considerable lack of understanding of viral latency processes. A lot of research has been conducted to study and clarify such mechanisms and propose strategies to eradicate the virus (sterilising cure) or at least permanently control it (functional cure) in order to bypass the need for chronic antiretroviral therapy. The purpose of this literature review is to discuss the state of the art in HIV‑1 research, with a particular focus on the mechanisms by which HIV‑1 eradication has thus far remained an unattainable goal. Future perspectives for the development of a functional or sterilising cure to HIV‑1 infection will also be explored.
HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing

Danielle E Lyons,Priti Kumar,Nadia R Roan,Patricia A Defechereux,Cedric Feschotte,Ulrike C Lange,Niren Murthy,Pauline Sameshima,Eric Verdin,Julie A Ake,Matthew S Parsons,Avindra Nath,Sara Gianella,Davey M Smith,Esper G Kallas,Thomas J Villa,Richard Strange,Betty Mwesigwa,Robert L Furler O'Brien,Douglas F Nixon,Lishomwa C Ndhlovu,Susana T Valente,Melanie Ott

DOI: https://doi.org/10.3390/v15112171

2023-10-28

Viruses

Abstract:Despite remarkable progress, a cure for HIV-1 infection remains elusive. Rebound competent latent and transcriptionally active reservoir cells persevere despite antiretroviral therapy and rekindle infection due to inefficient proviral silencing. We propose a novel "block-lock-stop" approach, entailing long term durable silencing of viral expression towards an irreversible transcriptionally inactive latent provirus to achieve long term antiretroviral free control of the virus. A graded transformation of remnant HIV-1 in PLWH from persistent into silent to permanently defective proviruses is proposed, emulating and accelerating the natural path that human endogenous retroviruses (HERVs) take over millions of years. This hypothesis was based on research into delineating the mechanisms of HIV-1 latency, lessons from latency reversing agents and advances of Tat inhibitors, as well as expertise in the biology of HERVs. Insights from elite controllers and the availability of advanced genome engineering technologies for the direct excision of remnant virus set the stage for a rapid path to an HIV-1 cure.
Gene therapy for HIV infection

Carmen de Mendoza,Pablo Barreiro,Laura Benitez,Vicente Soriano

DOI: https://doi.org/10.1517/14712598.2015.967208

Abstract:Introduction: Highly active antiretroviral therapy has been the big paradigm for transforming HIV infection in a chronic disease. However, it requires lifelong administration as the HIV provirus integrated within infected cells cannot be eliminated and virus replication resumes following antiviral discontinuation. Cumulative toxicities, incomplete immune restoration, elevated cost, drug-drug interactions and selection of drug-resistant viruses are well-known limitations of prolonged HIV medication. Areas covered: The first proof-of-concept that HIV infection could be cured was the Berlin patient. By blocking infection of target cells, gene therapy may allow viral clearance from carriers or prevention of infection in newly exposed individuals. Advances in the field of gene-targeting strategies, T-cell-based approaches and human stem cells are revolutionizing the field. A series of ongoing and planned trials are testing gene therapy as HIV cure. The ultimate goal is the elimination of latent viral reservoirs in HIV-infected persons and the need for lifelong antiretroviral therapy. Following a search in PubMed, we have reviewed current gene therapy strategies investigated for HIV infection as well as the latest communications on HIV eradication presented at international conferences. Expert opinion: Multiple efforts are underway to reproduce the Berlin patient situation by engineering autologous T cells or hematopoietic stem cells resistant to HIV infection. There is no doubt that the major challenge is the elimination of latent viral reservoirs. With this goal in mind, we have entered a new era in the hope for HIV cure.
HIV Persistence, Latency, and Cure Approaches: Where Are We Now?

Tessa C. Chou,Nishad S. Maggirwar,Matthew D. Marsden

DOI: https://doi.org/10.3390/v16071163

2024-07-20

Viruses

Abstract:The latent reservoir remains a major roadblock to curing human immunodeficiency virus (HIV) infection. Currently available antiretroviral therapy (ART) can suppress active HIV replication, reduce viral loads to undetectable levels, and halt disease progression. However, antiretroviral drugs are unable to target cells that are latently infected with HIV, which can seed viral rebound if ART is stopped. Consequently, a major focus of the field is to study the latent viral reservoir and develop safe and effective methods to eliminate it. Here, we provide an overview of the major mechanisms governing the establishment and maintenance of HIV latency, the key challenges posed by latent reservoirs, small animal models utilized to study HIV latency, and contemporary cure approaches. We also discuss ongoing efforts to apply these approaches in combination, with the goal of achieving a safe, effective, and scalable cure for HIV that can be extended to the tens of millions of people with HIV worldwide.

virology
Harnessing immune cells to eliminate HIV reservoirs

Paula Grasberger,Abigail R. Sondrini,Kiera L. Clayton

DOI: https://doi.org/10.1097/coh.0000000000000840

2024-02-06

Current Opinion in HIV and AIDS

Abstract:Despite decades of insights about how CD8 + T cells and natural killer (NK) cells contribute to natural control of infection, additional hurdles (mutational escape from cellular immunity, sequence diversity, and hard-to-access tissue reservoirs) will need to be overcome to develop a cure. In this review, we highlight recent findings of novel mechanisms of antiviral cellular immunity and discuss current strategies for therapeutic deisgn.

immunology,infectious diseases
Gaining momentum: stem cell therapies for HIV cure

Amanda M. Buck,Brian H. LaFranchi,Timothy J. Henrich

DOI: https://doi.org/10.1097/coh.0000000000000859

2024-04-26

Current Opinion in HIV and AIDS

Abstract:Purpose of review Durable HIV-1 remission has been reported in a person who received allogeneic stem cell transplants (SCTs) involving CCR5 Δ32/Δ32 donor cells. Much of the reduction in HIV-1 burden following allogeneic SCT with or without donor cells inherently resistant to HIV-1 infection is likely due to cytotoxic graft-versus-host effects on residual recipient immune cells. Nonetheless, there has been growing momentum to develop and implement stem cell therapies that lead to durable long-term antiretroviral therapy (ART)-free remission without the need for SCT. Recent findings Most current research leverages gene editing techniques to modify hematopoietic stem cells which differentiate into immune cells capable of harboring HIV-1. Approaches include targeting genes that encode HIV-1 co-receptors using Zinc Finger Nucleases (ZFN) or CRISPR-Cas-9 to render a pool of adult or progenitor cells resistant to de-novo infection. Other strategies involve harnessing multipotent mesenchymal stromal cells to foster immune environments that can more efficiently recognize and target HIV-1 while promoting tissue homeostasis. Summary Many of these strategies are currently in a state of infancy or adolescence; nonetheless, promising preclinical and first-in-human studies have been performed, providing further rationale to focus resources on stem cell therapies.

immunology,infectious diseases
HIV Pol: does it offer therapeutic targets for HIV?

Camilla Muccini,Antonella Castagna

DOI: https://doi.org/10.1080/14728222.2024.2351510

IF: 6.797

2024-05-10

Expert Opinion on Therapeutic Targets

Abstract:KEYWORDS: One of the greatest challenges in the management of HIV infection is the search for new treatment strategies, including those aimed at achieving a functional or sterilizing cure. Although antiretroviral therapy (ART) has dramatically improved the survival and quality of life of people living with HIV (PLWH) over the years, treatment interruption leads to viral rebound; to date, no study has proven to be effective in achieving viral eradication [ Citation 1 , Citation 2 ]. However, increasing knowledge of the HIV genome is enabling the exploration of innovative potential therapeutic approaches.

pharmacology & pharmacy
Targeting HIV persistence in the tissue

Daan K.J. Pieren,Aleix Benítez-Martínez,Meritxell Genescà

DOI: https://doi.org/10.1097/coh.0000000000000836

2024-02-06

Current Opinion in HIV and AIDS

Abstract:HIV/AIDS remains a global health crisis, despite significant progress in antiretroviral therapy (ART). Although ART effectively suppresses viral replication in the bloodstream, it cannot completely eradicate the virus due to the establishment of viral reservoirs within highly divers tissue compartments and cell subsets. These reservoirs, which include a pool of long-lived latently infected cells, serve as a major obstacle to achieving an HIV cure. Therefore, developing strategies to reach, reactivate, and eliminate HIV persistence in tissues is a major goal in the HIV field.

immunology,infectious diseases
Advancing towards HIV-1 remission: Insights and innovations in stem cell therapies

Aditi Chatterjee,Aerielle Matsangos,Olga S Latinovic,Alonso Heredia,Giovannino Silvestri

DOI: https://doi.org/10.46439/stemcell.5.020

Abstract:Human immunodeficiency virus type 1 (HIV-1) continues to pose a significant global health challenge despite advances in combined antiretroviral therapy (cART), which has transformed HIV-1 infection from a fatal disease to a manageable chronic condition. However, cART is not curative, and its long-term use is associated with challenges such as pill burden, drug toxicities, and the emergence of drug-resistant viral strains. The persistence of active viral reservoirs necessitates lifelong treatment, highlighting the need for alternative therapeutic strategies capable of achieving HIV-1 remission or cure. Stem cell therapy has emerged as a promising approach to address these challenges by targeting latent viral reservoirs, restoring host immune function, and potentially achieving sustained viral suppression in the absence of cART. This review critically evaluates current scientific literature on stem cell therapies for HIV-1, focusing on three major approaches: 1) hematopoietic stem cell transplantation (HSCT), 2) gene therapy, and 3) cell-based immunotherapies. Each approach is examined in terms of its underlying mechanisms, clinical feasibility, recent advancements, and associated challenges. Furthermore, future research directions are discussed, emphasizing the optimization of the current treatment protocols, enhancement of safety and efficacy, and the importance of large-scale clinical trials with different cohorts (different HIV clades, different genders of participants, and pediatric HIV) to evaluate long-term outcomes that include effective and scalable HIV cure challenges. Collaborative efforts across multidisciplinary fields are needed to overcome existing barriers so to realize the full therapeutic potential of stem cell-based approaches for developing an effective and scalable remission or cure strategies.
New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs

Maria Marra,Alessia Catalano,Maria Stefania Sinicropi,Jessica Ceramella,Domenico Iacopetta,Romina Salpini,Valentina Svicher,Stefania Marsico,Stefano Aquaro,Michele Pellegrino

DOI: https://doi.org/10.3390/v16091484

2024-09-19

Viruses

Abstract:More than 80 million people worldwide have been infected with the human immunodeficiency virus (HIV). There are now approximately 39 million individuals living with HIV/acquired immunodeficiency syndrome (AIDS). Although treatments against HIV infection are available, AIDS remains a serious disease. Combination antiretroviral therapy (cART), also known as highly active antiretroviral therapy (HAART), consists of treatment with a combination of several antiretroviral drugs that block multiple stages in the virus replication cycle. However, the increasing usage of cART is inevitably associated with the emergence of HIV drug resistance. In addition, the development of persistent cellular reservoirs of latent HIV is a critical obstacle to viral eradication since viral rebound takes place once anti-retroviral therapy (ART) is interrupted. Thus, several efforts are being applied to new generations of drugs, vaccines and new types of cART. In this review, we summarize the antiviral therapies used for the treatment of HIV/AIDS, both as individual agents and as combination therapies, and highlight the role of both macrophages and HIV cellular reservoirs and the most recent clinical studies related to this disease.

virology
Strategies for HIV-1 suppression through key genes and cell therapy

Alyona Sorokina,Elizaveta Anchakova,Erdem Dashinimaev

DOI: https://doi.org/10.3389/fmed.2023.1259995

2023-11-29

Abstract:Human immunodeficiency virus type 1 (HIV-1) remains a significant challenge for global public health as limited therapeutic options are available for HIV-infected individuals receiving combination antiretroviral therapy. Additionally, individuals with HIV-1/acquired immunodeficiency syndrome (AIDS) complications have a reduced life expectancy. In recent decades, gene and cell-based strategies have shown promise in achieving a functional cure for HIV-1 infection. The outcomes of therapies with patients in Berlin and London have led to moderate optimism for a highly effective HIV-1 treatment. This review categorizes current strategies for HIV-1 treatment into RNA- and antibody-based therapies, cell and genome editing approaches, and methods for eradicating latent reservoirs. These findings demonstrate how the use of various anti-HIV-1 agents enhances our understanding of HIV-1 infection and may provide important insights for potential HIV-1 treatment.
Targeting Viral Transcription for HIV Cure Strategies

Jon Izquierdo-Pujol,Maria C. Puertas,Javier Martinez-Picado,Sara Morón-López

DOI: https://doi.org/10.3390/microorganisms12040752

IF: 4.5

2024-04-08

Microorganisms

Abstract:Combination antiretroviral therapy (ART) suppresses viral replication to undetectable levels, reduces mortality and morbidity, and improves the quality of life of people living with HIV (PWH). However, ART cannot cure HIV infection because it is unable to eliminate latently infected cells. HIV latency may be regulated by different HIV transcription mechanisms, such as blocks to initiation, elongation, and post-transcriptional processes. Several latency-reversing (LRA) and -promoting agents (LPA) have been investigated in clinical trials aiming to eliminate or reduce the HIV reservoir. However, none of these trials has shown a conclusive impact on the HIV reservoir. Here, we review the cellular and viral factors that regulate HIV-1 transcription, the potential pharmacological targets and genetic and epigenetic editing techniques that have been or might be evaluated to disrupt HIV-1 latency, the role of miRNA in post-transcriptional regulation of HIV-1, and the differences between the mechanisms regulating HIV-1 and HIV-2 expression.

microbiology
HIV Reservoirs and Treatment Strategies toward Curing HIV Infection

Kouki Matsuda,Kenji Maeda

DOI: https://doi.org/10.3390/ijms25052621

IF: 5.6

2024-02-24

International Journal of Molecular Sciences

Abstract:Combination antiretroviral therapy (cART) has significantly improved the prognosis of individuals living with human immunodeficiency virus (HIV). Acquired immunodeficiency syndrome has transformed from a fatal disease to a treatable chronic infection. Currently, effective and safe anti-HIV drugs are available. Although cART can reduce viral production in the body of the patient to below the detection limit, it cannot eliminate the HIV provirus integrated into the host cell genome; hence, the virus will be produced again after cART discontinuation. Therefore, research into a cure (or remission) for HIV has been widely conducted. In this review, we focus on drug development targeting cells latently infected with HIV and assess the progress including our current studies, particularly in terms of the "Shock and Kill", and "Block and Lock" strategies.

biochemistry & molecular biology,chemistry, multidisciplinary
Humanized mice for studying HIV latency and potentially its eradication

Moa F. Hasler,Roberto F. Speck,Nicole P. Kadzioch

DOI: https://doi.org/10.1097/coh.0000000000000855

2024-04-05

Current Opinion in HIV and AIDS

Abstract:The quest for an HIV cure faces a formidable challenge: the persistent presence of latent viral infections within the cells and tissues of infected individuals. This review provides a thorough examination of discussions surrounding HIV latency, the use of humanized mouse models, and strategies aimed at eliminating the latent HIV reservoir. It explores the hurdles and advancements in understanding HIV pathogenesis, mainly focusing on establishing latent reservoirs in CD4 + T cells and macrophages. Introducing the concepts of functional and sterile cures, the review underscores the indispensable role of humanized mouse models in HIV research, offering crucial insights into the efficacy of cART and the ongoing pursuit of an HIV cure.

immunology,infectious diseases
Recent developments in CCR5 regulation for HIV cure

Krati Garg,Amir Riyaz Khan,Pankaj Taneja

DOI: https://doi.org/10.1016/bs.apcsb.2021.01.004

Abstract:Acquired immunodeficiency syndrome (AIDS) has affected millions of people worldwide. The human immunodeficiency virus (HIV) which infects T cells by using CD4 as its main receptor. Currently different treatments are available against HIV infection which can improve life expectancy of the patient but still it remains incurable. CCR5, which is also required as a co-receptor by majority of HIV strains for entry into the target cells, is now being targeted for gene therapy to develop HIV resistance in patients. In this review, we discuss different strategies that are being adapted for CCR5-gene disruption in CD4+ T cells and in hematopoietic stem cells (HSCs) to generate a HIV-resistant immune system in infected individuals. If CCR5 gene that can shape HIV-resistant T cells, it will aim in new approaches in clinical trials. But these techniques have certain weaknesses and disadvantages, and will need to be paired with other strategies to form a full HIV remedy. There is also a need to establish methods to help deter HIV re-emergence following targeted CCR5 therapy. But ultimately, this brought us a better knowledge of the road to HIV treatment.

New molecular therapies for hepatocellular carcinoma.

Current approaches to assess HIV-1 persistence

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

Advanced Therapies for Human Immunodeficiency Virus

Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection

Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure

Treatment of Human Immunodeficiency Virus-1: Current Challenges and Future Perspectives

HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing

Gene therapy for HIV infection

HIV Persistence, Latency, and Cure Approaches: Where Are We Now?

Harnessing immune cells to eliminate HIV reservoirs

Gaining momentum: stem cell therapies for HIV cure

HIV Pol: does it offer therapeutic targets for HIV?

Targeting HIV persistence in the tissue

Advancing towards HIV-1 remission: Insights and innovations in stem cell therapies

New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs

Strategies for HIV-1 suppression through key genes and cell therapy

Targeting Viral Transcription for HIV Cure Strategies

HIV Reservoirs and Treatment Strategies toward Curing HIV Infection

Humanized mice for studying HIV latency and potentially its eradication

Recent developments in CCR5 regulation for HIV cure